List view / Grid view

multiple myeloma



T-cell redirecting bispecific antibodies: the next era of immune-based therapies for multiple myeloma?

20 September 2022 | By

While the introduction of novel immunotherapies to combat and treat cancer has advanced patient care greatly, ever more effective solutions continue to be required. Here, Dr Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haemato-Oncology at Janssen Europe, Middle East & Africa (EMEA), explores how T-cell redirecting bispecific antibodies (TRBAs)…


Takeda to enrol 5000 patients in giant multiple myeloma trial

1 September 2016 | By Niamh Louise Marriott, Digital Content Producer

Takeda’s global non-interventional, observational multiple myeloma study is now enrolling patients, aiming to have 5,000 patients over three years with a goal of following each patient for a minimum of five years in an effort to track patterns in disease presentation, patient characteristics, treatment and outcomes, thereby enhancing the understanding…